The fate of human Langerhans cells in hematopoietic stem cell transplantation

被引:100
|
作者
Collin, MP [1 ]
Hart, DNJ
Jackson, GH
Cook, G
Cavet, J
Mackinnon, S
Middleton, PG
Dickinson, AM
机构
[1] Univ Newcastle Upon Tyne, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England
[2] Mater Med Res Inst, Brisbane, Qld 4101, Australia
[3] St James Univ Hosp, Dept Haematol, Leeds LS9 7TF, W Yorkshire, England
[4] Christie Hosp NHS Trust, Dept Haematol, Manchester M20 4BX, Lancs, England
[5] Royal Free & UCL, Sch Med, Dept Haematol, London NW3 2QG, England
来源
JOURNAL OF EXPERIMENTAL MEDICINE | 2006年 / 203卷 / 01期
关键词
D O I
10.1084/jem.20051787
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Langerhans cells (LC) and other antigen-presenting cells are believed to be critical in initiating graft versus host responses that influence the outcome of allogeneic hematopoietic stem cell transplantation. However, their fate in humans is poorly understood. We have sought to define the effect of conditioning regimes and graft versus host disease (GVHD) on the survival of recipient LC and reconstitution of donor cells after transplant. Confocal microscopy of epidermal sheets shows that full intensity transplant ( FIT) depletes LC more rapidly than reduced intensity transplant (RIT) at day 0, although the nadir is similar in both at 14-21 d. Recovery occurs rapidly within 40 d in the absence of acute GVHD, but is delayed beyond 100 d when GVHD is active. LC chimerism was determined in sex-mismatched transplants using a two-step Giemsa/fluorescence in situ hybridization assay on isolated cells. Acquisition of donor chimerism at 40 d is more rapid after FIT (97%) than RIT (36.5%), irrespective of blood myeloid engraftment. At 100 d, all transplants achieve at least 90% LC donor chimerism and over half achieve 100%. Complete donor chimerism is associated with prior acute cutaneous GVHD, suggesting a role for allogeneic T cells in promoting LC engraftment.
引用
收藏
页码:27 / 33
页数:7
相关论文
共 50 条
  • [41] Regulation of hematopoietic stem cell fate
    Krause, DS
    ONCOGENE, 2002, 21 (21) : 3262 - 3269
  • [42] Hematopoietic stem cell transplantation in patients with severe Langerhans cell histiocytosis and hematological dysfunction: Experience of the French Langerhans Cell Study Group
    Akkari, V
    Donadieu, J
    Piguet, C
    Bordigoni, P
    Michel, G
    Blanche, S
    Casanova, JL
    Thomas, C
    Vilmer, E
    Fischer, A
    Bertrand, Y
    BONE MARROW TRANSPLANTATION, 2003, 31 (12) : 1097 - 1103
  • [43] Hematopoietic stem cell transplantation in patients with severe Langerhans cell histiocytosis and hematological dysfunction: Experience of the French Langerhans Cell Study Group
    V Akkari
    J Donadieu
    C Piguet
    P Bordigoni
    G Michel
    S Blanche
    J L Casanova
    C Thomas
    E Vilmer
    A Fischer
    Y Bertrand
    Bone Marrow Transplantation, 2003, 31 : 1097 - 1103
  • [44] Cell cycle regulation and cell fate decisions in hematopoietic stem cells.
    Passegue, E
    Wagers, AJ
    Giuriato, S
    Anderson, WC
    Weissman, IL
    BLOOD, 2005, 106 (11) : 391A - 391A
  • [45] The role of mesenchymal stem cells in hematopoietic stem cell transplantation park
    S, K
    Won, J
    Kim, S
    Kim, H
    Kim, C
    Lee, N
    Lee, K
    Hong, D
    Park, H
    EXPERIMENTAL HEMATOLOGY, 2003, 31 (07) : 178 - 179
  • [46] The potential use of mesenchymal stem cells in hematopoietic stem cell transplantation
    Eun-Jung Kim
    Nayoun Kim
    Seok-Goo Cho
    Experimental & Molecular Medicine, 2013, 45 : e2 - e2
  • [47] Clinical Consideration for Mesenchymal Stem Cells in Hematopoietic Stem Cell Transplantation
    Wu, Kang-Hsi
    Chan, Chin-Kan
    Chao, Yu-Hua
    Peng, Ching-Tien
    Huang, Jing-Long
    TRANSPLANTATION, 2013, 96 (12) : E86 - E87
  • [48] The potential use of mesenchymal stem cells in hematopoietic stem cell transplantation
    Kim, Eun-Jung
    Kim, Nayoun
    Cho, Seok-Goo
    EXPERIMENTAL AND MOLECULAR MEDICINE, 2013, 45 : e2 - e2
  • [49] Outcomes of co-transplantation of mesenchymal stem cells and hematopoietic stem cells compared to hematopoietic stem cell transplantation alone in β-thalassemia patients
    Ghavamzadeh, A.
    Ranjbar, H.
    Nikbakht, M.
    Alimoghaddam, K.
    Vaezi, M.
    Bahar, B.
    Mousavi, S. A.
    Foumani, H. Kamranzadeh
    Kasaeian, A.
    Jahani, M.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S226 - S226
  • [50] DIRECTED DIFFERENTIATION OF HUMAN PLURIPOTENT STEM CELLS TO A DEFINITIVE HEMATOPOIETIC FATE
    Keller, Gordon
    Kennedy, Marion
    Sturgeon, Christopher
    Ditadi, Andrea
    Zuniga-Pfluecker, Juan Carlos
    Awong, Geneve
    EXPERIMENTAL HEMATOLOGY, 2012, 40 (08) : S25 - S26